CVKD

Cadrenal Therapeutics, Inc. - Common Stock (CVKD)

About Cadrenal Therapeutics, Inc. - Common Stock (CVKD)

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Details

Daily high

$13.05

Daily low

$12.60

Price at open

$12.98

52 Week High

$22.90

52 Week Low

$5.70

Market cap

25.5M

Dividend yield

0.00%

Volume

42,996

Avg. volume

32,892

P/E ratio

-1.40

Cadrenal Therapeutics, Inc. - Common Stock News